Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Lists 125 New Medical Devices For NHI Coverage

This article was originally published in PharmAsia News

Executive Summary

TOKYO - The Central Social Insurance Medical Council (Chuikyo), the Ministry of Health, Labor and Welfare panel that decides National Health Insurance listing and prices of drugs and medical devices, approved 125 new medical devices, parts and materials for NHI coverage Aug. 27, according to the MHLW

You may also be interested in...



Japan’s Corporate Health Insurance Financial Conditions Worsen

TOKYO - Squeezed by soaring treatment costs and shrinking participation, Japan's corporate health insurance providers suffered a steep fall in their balance sheets in fiscal 2007, ended in March 2008, an insurance lobby reported Sept. 10, while predicting that as many as 90 percent of them would suffer operating deficits in fiscal 2008

Pfizer And Astellas Drugs Added To Japan MHLW's NHI Coverage List

TOKYO - Japan's Ministry of Health, Labor and Welfare released details of 11 new drugs approved at the Aug. 27 Central Social Insurance Medical Council (Chuikyo) general meeting for National Health Insurance coverage listing

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel